Compare Repligen Corporation Common Stock (RGEN) vs PT Telekomunikasi Indonesia Tbk (TLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs PT Telekomunikasi Indonesia Tbk — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while PT Telekomunikasi Indonesia Tbk trades at $12.71 (market cap $12.31B). The key difference: Repligen Corporation Common Stock and PT Telekomunikasi Indonesia Tbk are close in size by market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and PT Telekomunikasi Indonesia Tbk for 1 Days on average.
| RGEN | TLK | |
|---|---|---|
Market Cap | $11.14B | $12.31B |
Volume | 1,259,263 | 964,895 |
Sector | Health | Media |
52-Week High | $194.57 | $23.43 |
52-Week Low | $102.87 | $12.42 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $11.02B | $13.67B |
Dividend Yield | — | 9.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →
